When Cell and Gene Therapies Surge to Market, How Resilient Will Your Cell Sourcing Infrastructure Be?
Nullam velit nulla commodo sem, at egestas nulla metus vel imperdiet aptent taciti ad litora torquent per.
Using Patient Outcomes Data to Inform and Advance the Development of Emerging Cell and Gene Therapies
View this on-demand webinar for an in-depth discussion on patient outcomes tracking through registries and how leveraging outcomes data collected from the first-generation of approved cell and gene therapies can inform the advancement of future cell and gene therapy products. Also included is a Q&A session between live webinar attendees and the following experts: Marcelo…
Understanding Donor Characteristics to Improve Allogeneic Cell Therapy Outcomes for All
Can donor-reported characteristics, like race and ethnicity, impact data quality for allogeneic cell therapies? That’s one of the questions our expert panelists will discuss during our upcoming webinar. You’ll walk away with a better understanding of: Efficiencies in donor selection to reduce uncertainties about HLA matching and improve patient outcomes HLA complexity in cell source selection How machine…
UK Review and Recommendations on the Procurement of Starting Materials by Apheresis for ATMP Manufacture
To ensure safe, high-quality Advanced Therapy Medicinal Products (ATMPs) are delivered to patients, procurement activities must be standardized when possible. Standardization also supports efficiency and reduces the risk for error while meeting regulatory and accreditation requirements. Download the UK Review and Recommendations on the Procurement of Starting Materials by Apheresis for ATMP Manufacture for insights…
The role of AI in predicting stem cell donor availability
For allogeneic cell therapy developers, donor availability is a critical factor. Without a donor, there is no therapy. Watch this webinar to learn how groundbreaking AI-based approaches, like the NMDPSM Donor Readiness Score, can predict the availability of every registered donor and evaluate the predictive power during donor selection. Our expert panel will explain how to: Predict an…
The Historical HLA Learning Curve
Human leukocyte antigens (HLAs), which are proteins found on the surface of most human cells, are fundamental to the success of matching potentially life-saving donors with patients in need of a blood stem cell transplant. Immune cells use HLAs to protect one’s own cells from invading microbes and viruses. A properly functioning immune system will…
The EBMT/EHA CAR-T Cell Handbook
A joint venture between the European Society of Blood and Marrow Transplantation (EBMT) and the European Hematology Association (EHA), the CAR-T Cell Handbook offers clinical care applications for health care professionals in the EU that treat patients with CAR-T cell therapies. Download the guide for insights into many aspects of CAR-T cell therapies including: The…
The Challenge of Multiple Audits and Redundant Training
As UCLA Health continues to participate in multiple CAR-T and other immunotherapy clinical trials, its apheresis unit and cell therapy lab continue to experience an increase in the need for their cell collection and processing services. Guest author, Heather Steinmetz, MPH, Quality Assurance Manager, UCLA Health Hematologic Malignancy/Stem Cell Transplant Program, shares some of the…
Streamlining Your Supply Chain to Support Next-Gen Therapies
As your cell and gene therapies move from early-phase clinical trials to commercialization, your supply chain complexity—and risk—increases. Anticipating setbacks and planning for their solution requires a specialized and collaborative approach with your supply chain partner. During this on-demand webinar, you’ll hear from industry experts who offer insights into developing a commercial supply chain for emerging autologous and allogeneic…